AI firm Neurophet expands reach in U.S.

Seoul, South Korea-based brain imaging AI developer Neurophet is expanding its reach into U.S. health systems with the integration of its neurodegenerative disease software into RapidAI’s Rapid Enterprise platform. 

The first product to be integrated is Neurophet Aqua AD Plus, which analyzes brain MRI to automatically monitor potential treatment-related side effects in patients with Alzheimer’s disease receiving anti-amyloid therapies, according to the company. 

Distribution initially will focus on U.S. memory disorders centers, the company noted. Later software integrations will extend to Neurophet Aqua, Neurophet Scale PET, and Neurophet Aqua MS, company officials said. Radiologists will access results through Rapid Navigator Pro and clinicians through the Rapid Mobile App.